SCHEMBL31069780

SCHEMBL31069780

COc1ccc(C(N)=O)c(F)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NNMT P40261 4/20 0.67
POLB P06746 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
MKNK1 Q9BUB5 2/20 0.41
MKNK2 Q9HBH9 2/20 0.41
PDE10A Q9Y233 1/20 0.40
SIRT6 Q8N6T7 1/20 0.40
JAK2 O60674 1/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GLA P06280 1/20 0.37
GAA P10253 1/20 0.37
DGAT1 O75907 1/20 0.37
TSHR P16473 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MTNR1A P48039 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9040184 0.84 TDP1 (0.66) NNMTPOLBTDP1KDM4ERAB9A
SCHEMBL27248156 0.84 POLB (0.51) NNMTPOLBTDP1KDM4ERAB9A
SCHEMBL28708856 0.82 POLB (0.50) NNMTPOLBTDP1KDM4ERAB9A
SCHEMBL30708511 0.82 POLB (0.50) NNMTPOLBTDP1KDM4ERAB9A
SCHEMBL27248204 0.80 POLB (0.47) NNMTPOLBTDP1KDM4ERAB9A
SCHEMBL6309037 0.80 NNMT (1.00) NNMTPOLBTDP1MKNK1MKNK2
SCHEMBL5010608 0.80 POLB (0.71) NNMTPOLBTDP1MKNK1MKNK2
SCHEMBL29421563 0.80 NNMT (1.00) NNMTPOLBTDP1MKNK1MKNK2
SCHEMBL5815928 0.80 NNMT (0.69) NNMTPOLBTDP1MKNK1MKNK2
SCHEMBL6305051 0.79 NNMT (0.67) NNMTPOLBTDP1MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 NNMT 3703/4885POLB 4440/4885TDP1 3121/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 NNMT 3703/4885POLB 4440/4885TDP1 3121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.